StockDocs
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
JAGX

Jaguar Health, Inc.

JAGX Nasdaq Pharmaceutical Preparations EDGAR ↗
$1.00
-0.04 -3.85%

Key statistics

from XBRL data in SEC filings
Market cap
$516K
Revenue (TTM)
$29.6M
Net income (TTM)
$19.1M
EPS (TTM)
$547.88
P/E ratio
0.0
Dividend yield
Free cash flow
-$23.7M
Cash
$7.28M
Total assets
$37.4M
Gross margin
52-week range
$0.91 – $92.75

Recent SEC filings

40 most recent
Annual, quarterly & current reports
8-K Entered a material agreement Jul 14, 2026 8-K Other events Jul 1, 2026 8-K Entered a material agreement; Other events Jun 25, 2026 8-K/A Regulation FD disclosure Jun 22, 2026 8-K Regulation FD disclosure Jun 22, 2026 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Jun 18, 2026 8-K Entered a material agreement; Unregistered sale of equity; Amended charter or bylaws Jun 11, 2026 8-K Shareholder vote results; Regulation FD disclosure Jun 8, 2026 8-K Entered a material agreement; Unregistered sale of equity; Other events Jun 2, 2026 8-K Regulation FD disclosure; Other events May 27, 2026 8-K Entered a material agreement; Other events May 22, 2026 8-K Results of operations (earnings release) May 20, 2026 10-Q Quarter ended 2026-03-31 May 20, 2026 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity; Amended charter or bylaws May 19, 2026 8-K Other events May 7, 2026 8-K Other events May 4, 2026 8-K Delisting notice or listing-rule failure May 4, 2026 8-K Delisting notice or listing-rule failure; Modified rights of security holders; Amended charter or bylaws; Regulation FD disclosure Apr 27, 2026 8-K Amended charter or bylaws; Shareholder vote results; Regulation FD disclosure Apr 21, 2026 8-K Other events Apr 9, 2026 8-K Results of operations (earnings release) Apr 7, 2026 10-K Fiscal year ended 2025-12-31 Apr 7, 2026 8-K Entered a material agreement; Terminated a material agreement; Took on a direct financial obligation Mar 9, 2026 8-K Delisting notice or listing-rule failure Mar 6, 2026 8-K Amended charter or bylaws Mar 3, 2026 8-K Modified rights of security holders; Regulation FD disclosure; Other events Feb 18, 2026 8-K Entered a material agreement; Unregistered sale of equity Jan 23, 2026 8-K Entered a material agreement; Regulation FD disclosure Jan 15, 2026 8-K/A Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Jan 12, 2026 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Jan 12, 2026 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Jan 12, 2026 8-K Entered a material agreement; Unregistered sale of equity Dec 12, 2025 8-K Shareholder vote results; Regulation FD disclosure Dec 8, 2025 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Nov 19, 2025 8-K Entered a material agreement; Took on a direct financial obligation Nov 14, 2025 10-Q Quarter ended 2025-09-30 Nov 14, 2025 8-K Unregistered sale of equity Oct 3, 2025 8-K Entered a material agreement; Unregistered sale of equity Oct 1, 2025 8-K Entered a material agreement; Unregistered sale of equity; Amended charter or bylaws Sep 11, 2025 8-K Shareholder vote results; Regulation FD disclosure Aug 19, 2025